Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells

[1]  Yong He,et al.  Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 , 2020, Cell Death & Disease.

[2]  N. Agarwal,et al.  Investigational MET inhibitors to treat Renal cell carcinoma , 2019, Expert opinion on investigational drugs.

[3]  A. Chambery,et al.  Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells , 2019, Cancers.

[4]  A. Oza,et al.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine , 2019, CA: a cancer journal for clinicians.

[5]  Kuang-Tai Kuo,et al.  Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src/CD155/MIF functional pathway , 2019, Journal of Experimental & Clinical Cancer Research.

[6]  Jae Kwan Lee,et al.  CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer , 2019, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[7]  Galina A. Erikson,et al.  Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring , 2019, Nature.

[8]  Dokyoon Kim,et al.  Differential gene expression induced by Verteporfin in endometrial cancer cells , 2019, Scientific Reports.

[9]  D. Siemann,et al.  Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion , 2019, Oncotarget.

[10]  M. Shakibaei,et al.  Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells , 2018, Nutrients.

[11]  Zhiguang Li,et al.  YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. , 2018, Cancer discovery.

[12]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[13]  Zhaocai Zhou,et al.  Targeting IRF3 as a YAP agonist therapy against gastric cancer , 2018, The Journal of experimental medicine.

[14]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ , 2017, Science Signaling.

[15]  W. Guo,et al.  Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer , 2017, Medicine.

[16]  T. Espevik,et al.  Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness , 2017, The Journal of Biological Chemistry.

[17]  X. Qiu,et al.  Overexpression of Yes‐associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta‐analysis , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[18]  D. Carey,et al.  Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells , 2017, Oncotarget.

[19]  L. Sklar,et al.  Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts , 2016, Molecular Cancer Therapeutics.

[20]  Jia Jia,et al.  Verteporfin, a suppressor of YAP–TEAD complex, presents promising antitumor properties on ovarian cancer , 2016, OncoTargets and therapy.

[21]  Ping Huang,et al.  Overexpression of TAZ promotes cell proliferation, migration and epithelial-mesenchymal transition in ovarian cancer , 2016, Oncology letters.

[22]  P. Kroeger,et al.  Pathogenesis and heterogeneity of ovarian cancer , 2016, Current opinion in obstetrics & gynecology.

[23]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[24]  Claudia C. Preston,et al.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer , 2015, Cancer Immunology, Immunotherapy.

[25]  R. Drapkin,et al.  YAP Induces High-Grade Serous Carcinoma in Fallopian Tube Secretory Epithelial Cells , 2015, Oncogene.

[26]  C. Rancourt,et al.  Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers , 2015, BMC Cancer.

[27]  Jianmin Zhang,et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.

[28]  H. Jono,et al.  Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells , 2014, Oncotarget.

[29]  Tsuyoshi Saito,et al.  Prognostic Impact of Human Leukocyte Antigen Class I Expression and Association of Platinum Resistance with Immunologic Profiles in Epithelial Ovarian Cancer , 2014, Cancer Immunology Research.

[30]  M. Sudol,et al.  Yes-Associated Protein (YAP) Modulates Oncogenic Features and Radiation Sensitivity in Endometrial Cancer , 2014, PloS one.

[31]  F. Balkwill,et al.  Cancer cell‐derived lymphotoxin mediates reciprocal tumour–stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts , 2014, The Journal of pathology.

[32]  S. Canevari,et al.  Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma , 2013, BioMed research international.

[33]  Ning Li,et al.  Correction: Molecular Mechanisms of HMW Glutenin Subunits from 1Sl Genome of Aegilops longissima Positively Affecting Wheat Breadmaking Quality , 2013, PLoS ONE.

[34]  Li-juan Wang,et al.  Overexpression of YAP and TAZ Is an Independent Predictor of Prognosis in Colorectal Cancer and Related to the Proliferation and Metastasis of Colon Cancer Cells , 2013, PloS one.

[35]  P. Sujka-Kordowska,et al.  MDR Gene Expression Analysis of Six Drug-Resistant Ovarian Cancer Cell Lines , 2012, BioMed research international.

[36]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[38]  M. Bookman.  First-line chemotherapy in epithelial ovarian cancer. , 2012, Clinical obstetrics and gynecology.

[39]  J. Prat.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.

[40]  Tayyaba Hasan,et al.  Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. , 2010, Cancer research.

[41]  Joungmok Kim,et al.  The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. , 2010, Genes & development.

[42]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[43]  R. Bristow,et al.  Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. , 2009, Anticancer research.

[44]  D. Levine,et al.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. , 2009, Gynecologic oncology.

[45]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[46]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[47]  B. Monk,et al.  Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. , 2005, Gynecologic oncology.

[48]  H. Lage,et al.  RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. , 2004, Gynecologic oncology.

[49]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  U. Schmidt-Erfurth,et al.  Photodynamic therapy with verteporfin: A new treatment in ophthalmology , 2001, Seminars in ophthalmology.

[51]  A. Kulig,et al.  Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease , 2017, Cytokine.

[52]  B. Zhang,et al.  Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis , 2016, OncoTargets and therapy.

[53]  C. Rancourt,et al.  Profiling of cytokines in human epithelial ovarian cancer ascites. , 2012, American journal of cancer research.

[54]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[55]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.